← Back to headlines
Eli Lilly Reports Positive Phase 3 Results for Jaypirca Combination in CLL/SLL
Eli Lilly (LLY) announced positive Phase 3 results for its Jaypirca combination therapy in patients with relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
27 Jun, 11:21 — 27 Jun, 11:21
Sources
Showing 1 of 1 sources
